NCT05671666 Ureagenesis Analysis in Healthy Subjects and in Urea Cycle Disorder Patients
| NCT ID | NCT05671666 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Children's Hospital, Zurich |
| Condition | Urea Cycle Disorders |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2019-10-31 |
| Primary Completion | 2035-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2019-10-31 with a primary completion date of 2035-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Urea cycle disorders (UCDs) are dramatic congenital inherited metabolic disorders. There is no cure. Many novel therapeutic approaches are currently being developed, which hopefully will change the current situation. Testing the efficacy of such new therapies in patients is a challenge, because many clinical parameters are influenced by several disturbances and biochemical parameters are often not very specific. The measurement of ureagenesis is a tool to analyze the entire function of the urea cycle in a single test. This is more meaningful for the characterization of UCD patients than the analysis of single metabolites or enzymes. Therefore, the test will be important to evaluate current and future novel therapies. The term "ureagenesis" means "production of urea", which is the main task of the urea cycle. This total urea production can be measured with a "tracer" (in this case a stable ammonium chloride isotope). This tracer is non-radioactive and non-toxic. It is for example used as an unmarked substance in cough syrup, diuretic drugs and as food additive. Thus, the tracer does not pose a risk to the participant, especially since only a very low dose is applied. The investigators will analyze specific substances from the urea cycle (namely \[15N, 14N\] urea and several \[15N\] amino acids) that are produced during the test and compare them with results from healthy people. Venous and capillary blood will be sampled at 15 to 30 minutes intervals up to 2 hours after administration of the stable isotope tracer. The maximum test duration is 5 hours. This project is being carried out at one site, namely the University Children's Hospital in Zurich. This project is being carried out under Swiss law. The responsible Ethics Committee has reviewed and approved the study.
Eligibility Criteria
Inclusion Criteria: * healthy subjects at any age and given written informed consent * subjects with a UCD confirmed by genetic or enzymatic diagnostics at any age and given written informed consent Exclusion Criteria: * healthy subjects with acute and chronic disease requiring treatment of any kind * pregnant or lactating women. * UCD patients with acute and chronic (other than her/his UCD) disease requiring treatment * UCD patients in which intake of carglumic acid cannot be stopped for 24 hours prior to the test
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05671666 clinical trial?
This trial is open to participants of all sexes, studying Urea Cycle Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05671666 currently recruiting?
Yes, NCT05671666 is actively recruiting participants. Contact the research team at Johannes.haeberle@kispi.uzh.ch for enrollment information.
Where is the NCT05671666 trial being conducted?
This trial is being conducted at Zurich, Switzerland.
Who is sponsoring the NCT05671666 clinical trial?
NCT05671666 is sponsored by University Children's Hospital, Zurich. The trial plans to enroll 100 participants.